BioLegend, NY Genome Center Ink Exclusive Agreement for Transcriptome Tech
San Diego-based BioLegend has now licensed a multidimensional single-cell analysis technology from the New York Genome Center and is collaborating with the center on further research.
The CITE-seq™, Cellular Indexing of Transcriptomes and Epitopes by sequencing, developed in the NYGC’s Technology Innovation Lab complements BioLegend’s extensive portfolio of antibodies and biomedical reagents. The new CITE-seq™ technology enables scientists to simultaneously measure protein and RNA expression at the single-cell level, allowing researchers to distinguish different cell types and cell states, and study disease mechanisms at the level of individual cells.
BioLegend is currently providing customers with custom CITE-seq antibody conjugates and plans to offer CITE-seq catalog products in the future.
“The capacity of CITE-seq to more finely dissect cell populations has many potential applications in clinical research, and is a powerful tool in international efforts to create a human single cell atlas,” said Tom Maniatis, NYGC’s scientific director and CEO, in a statement. “Our CITE-seq license agreement and accompanying collaborative research agreement with BioLegend are good examples of how sharing innovative genomic tools widely with the scientific community has the potential to advance translational genomic science and advance efforts to realize the goals of precision medicine.
”“We are very excited about Dr. Stoeckius’ innovative technology, and its applicability to BioLegend’s portfolio of reagents for profiling protein expression in single cells. This approach will surely revolutionize basic and biomedical research. Along with other advancing technologies in this space, giving scientists easy access to quality reagents such as these will significantly accelerate scientific research,” says Gene Lay, BioLegend’s CEO.
